pharma
Y-mAbs Therapeutics
Y-Mabs Therapeutics A/S
Y-Mabs Therapeutics A/S is a pharma organization headquartered in EU. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USP
Company details
- Status
- Public
- HQ
- New York, USA
- Founded
- 2015
- Employees
- 68
- Programs
- 1
- Drugs
- 5
- Patents
- 0
201
Phase 2 · small molecule · Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow
201 for Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow is a Phase 2 program (small_molecule) at Y-Mabs Therapeutics A/S with 1 ClinicalTrials.gov record(s).
Internal code 201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Y-Mabs Therapeutics A/S
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow
- Status
- active
- Trials
- 1